Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma
10.3971/j.issn.1000-8578.2021.21.0108
- VernacularTitle:PD-1/PD-L1/2通路在多发性骨髓瘤中的研究进展
- Author:
Yinjuan MA
1
;
Xiaying YANG
;
Ying WANG
;
Xuan WANG
;
Yaozhu PAN
Author Information
1. Department of Hematology, The 940th Hospital of Joint Support Force of Chinese People's Liberation Army, Lanzhou 730050, China
- Publication Type:Research Article
- Keywords:
Multiple myeloma;
PD-1;
PD-L1;
PD-L2;
Immune checkpoint inhibitors
- From:
Cancer Research on Prevention and Treatment
2021;48(6):647-651
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma is a type of hematological malignancy caused by clonal plasma cell proliferation. In recent years, the application of proteasome inhibitors and immune drugs (IMiDs) in multiple myeloma has prolonged the survival period of patients and improved the quality of life. However, due to the heterogeneity, recurrence and drug resistance of the disease, MM is still incurable. Relatively good response rates of immune checkpoint inhibitors such as Pembrolizumab, Nivolumab, Pidilizumab, Atezolizumab and Durvalumab offer MM a new hope. This article reviews the relevant literature in recent years, introduces the immune pathogenesis of MM, PD-1/PD-L1/2-related immune pathway and the current status of immunotherapy, to provide reference for the immunotherapy of MM.
